About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Phase 2 Study of TLK286 in Metastatic Breast Cancer

NCT00035841·3 sites·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Telik

Age

18–any

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

Histologic diagnosis of breast cancer
Metastatic disease
Measurable or evaluable disease
No prior chemotherapy regimens
Age at least 18 years
Adequate liver and kidney function
Adequate bone marrow function

You may not be if

Pregnant or lactating women
Unstable medical conditions
Chemotherapy within 14 days of TLK286
Radiation therapy within 14 days of TLK286
Hormonal therapy within 14 days of TLK286
Immunotherapy within 14 days of TLK286
CNS metastasis unless controlled by treatment

The record

StatusCompleted

PhasePhase 2

Taking part60

StartedApr 2002

UpdatedJul 25, 2011

Conditions

Breast Neoplasms

Where3

Arizona Cancer Center
Tucson, Arizona, United States
Indiana University Medical Center
Indianapolis, Indiana, United States
Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio, United States

Clareo Health | Phase 2 Study of TLK286 in Metastatic Breast Cancer